Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Vascular Ultrasound in Percutaneous Closure Devices: Subanalysis of the UNIVERSAL-Trial

Analysis of percutaneous closure device placement when choosing an ultrasound-guided vs. a fluoroscopy-guided femoral approach.


Transradial access is the access of choice in percutaneous coronary interventions, with a demonstrated benefit in mortality and bleeding when compared with transfemoral access. The latter, however, is still the access of choice in cases where large caliber introducers are used or in cases where the transradial approach is not available.

Ecografía vascular en dispositivos de cierre percutáneo: Subanálisis del UNIVERSAL-Trial

Several studies have shown that the use of percutaneous closure devices (PCD) has reduced the time to hemostasis and time to ambulation when using the transfemoral approach.

The objective of this prespecified subanalysis of the UNIVERSAL-Trial was to explore the association between vascular ultrasound (US)-guided puncture and the use of PCD in terms of bleeding and vascular complications.

This was a multicenter, open-design, randomized study, which compared US-guided puncture vs. fluoroscopy-guided puncture for PCD placement in coronary procedures. Patients <18 years of age with coronary syndrome with ST elevation or absence of palpable femoral pulse were excluded. The subjects were randomized 1:1 and US was used exclusively for the puncture, not to guide PCD placement.

The primary endpoint (PEP) was a composite of BARC type 2, 3, or 5 bleeding, or a major vascular complication (femoral pseudoaneurysm, arteriovenous fistula, retroperitoneal bleeding, hematoma >5 cm in diameter, or limb ischemia requiring intervention within 30 days).

Read also: ACC 2023 | COORDINATE-DIABETES.

A total of 621 patients were randomized and followed-up. Out of all patients, 54.7% of patients in the US group and 51% in the fluoroscopy-guided puncture group received a PCD. 

Mean age was 70 years; 25.6% of subjects were female, 54.2% had a previous AMI, 39.9% had diabetes, and 54% had undergone a previous myocardial revascularization surgery. A 6Fr introducer sheath was used in 74.1% of cases; in 82% of all US-guided punctures the ANGIO-SEAL device was used. Successful common femoral cannulation was observed in 87.6% of all US-guided punctures compared with 90.4% in all non-guided punctures.

In patients who received a PCD, the US-guided approach showed a 66% reduction in the PEP (odds ratio [OR] 0.44; 95% confidence interval [CI]: 0.23-0.82), whereas in patients who did not receive a PCD, there were no significant differences (OR: 1.76; 95% CI: 0.80-4.03). The subgroup of patients in which the ANGIO-SEAL device was used experienced significantly fewer complications (OR: 0.33; 95% CI: 0.15-0.71), an effect not seen with the ProGlide device (OR: 0.74; 95% CI: 0.14-3.31).

Read also: Mechanical Aspiration in ST Elevation ACS.

The benefit of ultrasound use was at the expense of vascular complications (OR: 0.28; 95% CI: 0.10-0.71), with no differences observed in patients where PCDs were not used. There were no differences in bleeding for either group. Hematomas <5cm were 3 times more frequent when the PCD was placed without ultrasound guidance.

Conclusions

When deciding to place a percutaneous closure device in coronary procedures, ultrasound guidance of the transfemoral puncture significantly decreased vascular complications, with no changes in BARC 2, 3, or 5 type bleeding. Since this study was conducted in a subgroup, this hypothesis should be considered regarding the routine use of US for this type of device.

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Original Title: Ultrasound-guided femoral access in patients with vascular closure devices: a prespecified analysis of the randomised UNIVERSAL trial.

Reference: d’Entremont MA, Alrashidi S, Alansari O, et al. Ultrasound-guided femoral access in patients with vascular closure devices: a prespecified analysis of the randomised UNIVERSAL trial [published online ahead of print, 2023 Feb 25]. EuroIntervention. 2023;EIJ-D-22-01130. doi:10.4244/EIJ-D-22-01130.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...